Biotech Values

[dewophile]

ENTA

Evidently, ribavirin is not needed for GT1b patients, either treatment-naive, or treatment-experienced, but its is needed for GT1a patients

Even though ribavirin adds to efficacy in G1a pts the fact that there was 90% SVR without rib is still meaningful when messaging docs IMO. ABBV can now reassure docs that for pts who require dose reductions or stopping rib their cure rates should still be very good

obviously I agree w your bottom line and this was about as good an outcome as could be expected (and in fact about 5% better than I had predicted in a previous post)